The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
News|Articles|April 27, 2026
Raising Testicular Cancer Awareness Enhances Treatment Decision-Making and Survivorship Care
Author(s)Kyle Doherty
Fact checked by: Courtney Flaherty
Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.
Advertisement
Advertisement
Although 5-year relative survival rates remain high for patients with testicular cancer, early detection, continued advances in treatment approaches, and enhanced care for survivors are crucial to further improving outcomes for patients, according to Mina M. Fam, MD.
Related to this article
TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.
Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
R. Lor Randall, MD, FACS, outlines how AI may affect oncology training, how to properly work alongside AI, and AI-patient conversations.
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
Advertisement
Advertisement